Ask AI
ProCE Banner Activity

EMBRACE: Safety and Tolerability of VH3810109 (N6LS) in People With Virologically Suppressed HIV

Conference Coverage
Slideset

Part 1 of the Phase IIb EMBRACE study of N6LS, a broadly neutralizing antibody (bNAb), suggests safety and tolerability when administered IV or SC every 4 months in combination with long-acting cabotegravir (LA CAB).

Released: October 22, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare